Director, Bioanalysis

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102 for the treatment of patients with neurodegenerative disorders, and ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#TeamArvinas is made up of approximately 280 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

For more information, please visit www.arvinas.com. 

Position Summary 

We have an exciting opening for a seasoned bioanalytical scientist with expertise in the area of small molecule bioanalysis. The incumbent will contribute as a bioanalytical expert supporting drug discovery through all stages of drug development, with a focus on regulated bioanalysis for nonclinical GLP programs and clinical programs.  

This position reports to the Vice President Nonclinical Sciences and can work with a hybrid or remote work arrangement from a location within the United States. 

 

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

• Contribute to the formulation and execution of bioanalytical strategy supporting all facets of Arvinas bioanalytical needs from a project, portfolio, or functional levels.
• Participate in the non-regulated bioanalytical support for in vitro ADME, preclinical in vivo PK, ADME, and PK/PD studies, DRF toxicology studies and regulated and GLP-compliant bioanalytical work for GLP toxicology and clinical pharmacology.
• Contribute to bioanalysis outsource strategy; evaluate, recommend, or select bioanalytical CROs to ensure timely and stage-appropriate bioanalytical support of Arvinas projects.
• Serve as Arvinas SME and oversee the development, qualification, or validation of bioanalytical methods for various matrices and species
• Serve as Arvinas representative to coordinate all facets of bioanalysis and ensure timely delivery of high-quality bioanalytical results to support project progression and decision-making.
• Ensure high quality and regulatory compliance for all Arvinas regulated bioanalytical work.
• Stay up to date with the scientific advance and evolving domestic (FDA) and international (ICH, etc.) regulatory landscape for bioanalysis for the pharmaceutical industry.

Qualifications

• 10+ years of direct experi